Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAE1 | Q13564 | 13/20 | 0.63 |
| ▸ | UBA3 | Q8TBC4 | 13/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17145172 | 0.78 | NAE1 (0.76) | NAE1UBA3KCNH2OPRK1 | |
| SCHEMBL15007500 | 0.75 | NAE1 (0.66) | NAE1UBA3KCNH2HTR2B | |
| SCHEMBL15007406 | 0.73 | NAE1 (0.46) | NAE1UBA3 | |
| SCHEMBL3912788 | 0.69 | LMNA (0.44) | NAE1UBA3HTR2B | |
| SCHEMBL15007593 | 0.68 | NAE1 (0.61) | NAE1UBA3 | |
| SCHEMBL415622 | 0.67 | CALM1 (0.50) | NAE1UBA3HTR2B | |
| SCHEMBL18526995 | 0.67 | NAE1 (0.67) | NAE1UBA3KCNH2 | |
| SCHEMBL23487922 | 0.67 | NAE1 (0.57) | NAE1UBA3KCNH2OPRK1 | |
| SCHEMBL23456068 | 0.67 | NAE1 (0.57) | NAE1UBA3KCNH2OPRK1 | |
| SCHEMBL24348809 | 0.64 | HTR2B (0.41) | HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050935-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES | RCE1, ECE1, UBE2E1 | NAE1 24/4885UBA3 6/4885KCNH2 4797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.